

Published in final edited form as:

Science. 2003 May 16; 300(5622): 1140–1142. doi:10.1126/science.1082889.

Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance

Kitt Falk Petersen¹, Douglas Befroy^{1,7}, Sylvie Dufour^{1,7}, James Dziura¹, Charlotte Ariyan³, Douglas L. Rothman⁴, Loretta DiPietro^{5,6}, Gary W. Cline¹, and Gerald I. Shulman^{1,2,7,*}

¹Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA

²Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA

³Department of Surgery, Yale University School of Medicine, New Haven, CT 06520, USA

⁴Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA

⁵Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA

⁶John B. Pierce Laboratory, Yale University School of Medicine, New Haven, CT 06520, USA

⁷Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520, USA

Abstract

Insulin resistance is a major factor in the pathogenesis of type 2 diabetes in the elderly. To investigate how insulin resistance arises, we studied healthy, lean, elderly and young participants matched for lean body mass and fat mass. Elderly study participants were markedly insulin-resistant as compared with young controls, and this resistance was attributable to reduced insulin-stimulated muscle glucose metabolism. These changes were associated with increased fat accumulation in muscle and liver tissue assessed by ¹H nuclear magnetic resonance (NMR) spectroscopy, and with a ~40% reduction in mitochondrial oxidative and phosphorylation activity, as assessed by in vivo ¹³C/³¹P NMR spectroscopy. These data support the hypothesis that an age-associated decline in mitochondrial function contributes to insulin resistance in the elderly.

Type 2 diabetes is the most common chronic metabolic disease in the elderly, affecting ~30 million individuals 65 years of age or older in developed countries (1). The estimated economic burden of diabetes in the United States is ~\$100 billion per year, of which a substantial proportion can be attributed to persons with type 2 diabetes in the elderly age group (2). Epidemiological studies have shown that the transition from the normal state to overt type 2 diabetes in aging is typically characterized by a deterioration in glucose

*To whom correspondence should be addressed. gerald.shulman@yale.edu.

Supporting Online Material: www.sciencemag.org/cgi/content/full/300/5622/1140/DC1

Materials and Methods

SOM Text

Figs. S1 and S2

References

tolerance (3,4) that results from impaired insulin-stimulated glucose metabolism in skeletal muscle (5,6). Measurements of muscle triglyceride content by biopsy (7) or intramyocellular lipid content (IMCL) by ^1H nuclear magnetic resonance (NMR) spectroscopy (8–10) have shown a strong relationship between increased intramuscular fat content and insulin resistance in muscle. Similar correlations have been established for hepatic insulin resistance and hepatic steatosis (11–13). Increases in the intracellular concentration of fatty acid metabolites have been postulated to activate a serine kinase cascade leading to defects in insulin signaling in muscle (14–17) and the liver (18), which results in reduced insulin-stimulated muscle glucose transport activity (14), reduced glycogen synthesis in muscle (19,20), and impaired suppression of glucose production by insulin in the liver (11–13).

To examine whether insulin resistance in the elderly is associated with similar increases in intramyocellular and/or liver triglyceride content, we studied healthy elderly and young people that we matched for lean body mass (LBM) and fat mass. All study participants were non-smoking, sedentary, lean [body mass index (BMI) < 25 m²/kg], and taking no medications. Sixteen elderly volunteers (ages 61 to 84 years, 8 male and 8 female) were screened with a 3-hour oral glucose (75 g) tolerance test and underwent dual-energy x-ray absorptiometry to assess LBM and fat mass (21). One elderly man was excluded from the study because of an abnormal glucose profile. Thirteen young volunteers (ages 18 to 39 years, 6 male and 7 female), who had no family history of diabetes or hypertension, were matched to the older participants for BMI and habitual physical activity, which was assessed by means of an activity index questionnaire (22). All participants underwent a complete medical history and physical examination, as well as blood tests to confirm that they were in excellent health (23).

Young and elderly participants had similar fat mass, percent fat mass, and LBM (Table 1) (24). The elderly participants had slightly higher plasma glucose concentrations (Fig. 1A) and significantly higher plasma insulin concentrations (Fig. 1B) during the oral glucose tolerance test, suggesting that they were relatively insulin-resistant as compared with the young controls. Basal plasma fatty acid concentrations (Fig. 1C) also tended to be higher in the elderly participants but were suppressed normally after glucose ingestion.

To determine what tissues were responsible for the insulin resistance, we performed hyperinsulinemic-euglycemic clamp studies, in combination with [6,6- $^2\text{H}_2$] glucose and [$^2\text{H}_5$] glycerol tracer infusions (24). Basal rates of glucose production were similar in the young and elderly participants (Table 2) and were suppressed completely in both groups during the hyperinsulinemic-euglycemic clamp. In contrast, the rates of glucose infusion required to maintain euglycemia during the clamp and insulin-stimulated rates of peripheral glucose uptake were ~40% lower in the elderly participants (Table 2). Basal energy expenditure and respiratory quotient both tended to be lower in the elderly participants (24).

To ascertain whether lipid accumulation in muscle might be responsible for the insulin resistance in the elderly participants, we used ^1H NMR spectroscopy to assess IMCL and hepatic triglyceride content (24). The IMCL content in the soleus muscle was increased by ~45% in the elderly participants as compared with controls (Table 2 and fig. S1). Intrahepatic triglyceride content was also increased by 225% in the elderly participants as compared with controls, even though there was no detectable hepatic insulin resistance in the elderly participants during the clamp. It is possible that hepatic insulin resistance was not detected in the elderly participants because of the relatively high plasma insulin concentrations obtained during the clamp studies, which completely suppressed hepatic glucose production in both groups.

Because increases in intramyocellular and intrahepatic triglyceride content could occur secondarily to increased fatty acid delivery from lipolysis, we also examined this process in vivo. We assessed whole-body and subcutaneous fat lipolysis by measuring the rates of [²H₅] glycerol turnover in combination with microdialysis measurements of glycerol release from subcutaneous fat. Basal rates of whole-body glycerol turnover and insulin suppression of glycerol turnover during the clamp were similar in the elderly and control participants. Consistent with this finding, the interstitial glycerol concentrations, assessed by microdialysis, decreased by a similar degree during the clamp in both groups. Taken together, these data suggest that insulin resistance was confined mostly to skeletal muscle and that increased basal rates of peripheral lipolysis, and/or defects in insulin suppression of lipolysis, do not play a major role in causing the increased intramyocellular and intrahepatic triglyceride content in the elderly.

We and others (25) have previously hypothesized that defects in mitochondrial oxidative and phosphorylation capacity might be a contributing factor to the increased triglyceride content in muscle and the liver (26). To test this hypothesis, we assessed in vivo rates of mitochondrial oxidative activity in skeletal muscle by ¹³C NMR and phosphorylation activity by ³¹P NMR (24,27). Using this approach, we found that rates of mitochondrial oxidative and phosphorylation activity were both reduced by ~40% in the elderly participants as compared with the young controls. These in vivo results are consistent with those of a previous in vitro study, which found decreased state III (activated) mitochondrial respiration in isolated mitochondria from elderly participants (28). However, the latter study was performed with muscle strips, from orthopedic and chronic fatigue syndrome patients, under artificial substrate concentrations that do not reflect in vivo conditions.

Our results suggest that insulin resistance in the elderly is related to increases in intramyocellular fatty acid metabolites that may be a result of an age-associated reduction in mitochondrial oxidative and phosphorylation activity (fig. S2). The similarity in mitochondrial energy coupling, assessed by the ratio between adenosine triphosphate (ATP) synthase flux and tricarboxylic acid (TCA) cycle oxidation, suggests an age-associated reduction in mitochondrial number and/or function, as opposed to an acquired defect in mitochondrial energy coupling. These possibilities are consistent with a recent study demonstrating an age-associated accumulation of mutations in control sites for mitochondrial DNA replication (29). Because mitochondrial oxidative and phosphorylation activity is the major source of energy in most organs, including the brain, our data add support to the hypothesis that a decline in mitochondrial oxidative and phosphorylation energy production may also have an important role in aging (30,31). Furthermore, because mitochondrial energy metabolism plays a critical role in glucose-induced insulin secretion (32), similar age-associated reductions in pancreatic beta cell mitochondrial function, in the setting of peripheral insulin resistance, might help explain the high prevalence of diabetes in the elderly.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Y. Kossover, M. Smolgovsky, A. Romanelli, and the staff of the Yale/New Haven Hospital General Clinical Research Center for expert technical assistance and the volunteers for participating in this study. Supported by grants from the U.S. Public Health Service (K-23 DK-02347, R01 AG-09872, P60 AG-10469, P30 DK-45735, M01 RR-00125, and R01 DK-49230).

References and Notes

1. King H, Aubert RE, Herman WH. *Diabetes Care* 1998;21:1414. [PubMed: 9727886]
2. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. *JAMA* 1989;262:2708. [PubMed: 2509743]
3. Sasaki A, Suzuki T, Horiuchi N. *Diabetologia* 1982;22:154. [PubMed: 7075915]
4. Saad MF, et al. *Lancet* 1989;1:1356. [PubMed: 2567374]
5. Rowe JW, Minaker KL, Pallotta JA, Flier JS. *J Clin Invest* 1983;71:1581. [PubMed: 6345585]
6. Reaven GM. *Physiol Rev* 1995;75:473. [PubMed: 7624391]
7. Johnson AB, et al. *Clin Sci (London)* 1992;82:219. [PubMed: 1311661]
8. Krssak M, et al. *Diabetologia* 1999;42:113. [PubMed: 10027589]
9. Perseghin G, et al. *Diabetes* 1999;48:1600. [PubMed: 10426379]
10. Szczepaniak LS, et al. *Am J Physiol* 1999;276:E977. [PubMed: 10329993]
11. Petersen KF, et al. *J Clin Invest* 2002;109:1345. [PubMed: 12021250]
12. Kraegen EW, et al. *Diabetes* 1991;40:1397. [PubMed: 1936601]
13. Seppala-Lindroos A, et al. *J Clin Endocrinol Metab* 2002;87:3023. [PubMed: 12107194]
14. Griffin ME, et al. *Diabetes* 1999;48:1270. [PubMed: 10342815]
15. Dresner A, et al. *J Clin Invest* 1999;103:253. [PubMed: 9916137]
16. Yu C, et al. *J Biol Chem* 2002;277:50230. [PubMed: 12006582]
17. Itani SI, Ruderman NB, Schmieder F, Boden G. *Diabetes* 2002;51:2005. [PubMed: 12086926]
18. Kim JK, et al. *Proc Natl Acad Sci USA* 2001;98:7522. [PubMed: 11390966]
19. Boden G, Chen X, Ruiz J, White JV, Rossetti L. *J Clin Invest* 1994;93:2438. [PubMed: 8200979]
20. Roden M, et al. *J Clin Invest* 1996;97:2859. [PubMed: 8675698]
21. Petersen KF, et al. *Diabetes* 1998;47:381. [PubMed: 9519743]
22. Baecke JA, Burema J, Frijters JE. *Am J Clin Nutr* 1982;36:936. [PubMed: 7137077]
23. Written consent was obtained from each participant after the purpose, nature, and potential complications of the studies were explained. The protocol was approved by the Yale University Human Investigation Committee.
24. Materials and methods are available as supporting material on *Science* Online.
25. Kelley DE, He J, Menshikova EV, Ritov VB. *Diabetes* 2002;51:2944. [PubMed: 12351431]
26. Shulman GI. *J Clin Invest* 2000;106:171. [PubMed: 10903330]
27. Lebon V, et al. *J Clin Invest* 2001;108:733. [PubMed: 11544279]
28. Trounce I, Byrne E, Marzuki S. *Lancet* 1989;1:637. [PubMed: 2564459]
29. Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G. *Science* 1999;286:774. [PubMed: 10531063]
30. Harman D. *J Am Geriatr Soc* 1972;20:145. [PubMed: 5016631]
31. Linnane AW, Marzuki S, Ozawa T, Tanaka M. *Lancet* 1989;1:642. [PubMed: 2564461]
32. Luft R, Luthman H. *Lakartidningen* 1993;90:2770. [PubMed: 8366714]




Fig. 1.

Plasma concentrations of glucose, insulin, and fatty acids before and after an oral glucose tolerance test (24) in young and elderly participants. **(A)** Glucose [$P = 0.10$ for the area under the curve (AUC) for the elderly ($16,978 \pm 656$) as compared with the controls ($14,495 \pm 1,116$)]. **(B)** Insulin [asterisks indicate $P < 0.03$ for AUC for the elderly (6590 ± 853) as compared with the controls (3986 ± 519)]. **(C)** Fatty acids ($P = 0.08$ for the basal concentration of fatty acids in the elderly versus the controls).

Table 1

Body composition of study participants.

	Age (years)	Body weight (kg)	Fat mass (kg)	% Fat mass (% body weight)	LBM (kg)	BMI (kg/m ²)
Young (<i>n</i> = 13)	27 ± 2	71 ± 4	19.9 ± 2.5	28 ± 3	54 ± 5	23.8 ± 1.1
Elderly (<i>n</i> = 15)	70 ± 2	70 ± 3	20.1 ± 1.7	29 ± 2	49 ± 3	25.1 ± 0.5
<i>P</i> value	<0.0001	0.69	0.93	0.77	0.28	0.28

Table 2

Metabolic rates and tissue lipid content of participants (24).

	Basal rates of glucose production (mg/kg of LBM/min)	Clamp peripheral glucose metabolism rate (mg/kg of LBM/min)	Intramyocellular lipid content (%)	Intrahepatic lipid content (%)	Mitochondrial TCA flux rate (nmol/g of muscle/min)	Mitochondrial ATP synthesis rate (μ mol/g of muscle/min)
Young	2.3 \pm 0.1	6.2 \pm 0.6	0.96 \pm 0.08	0.49 \pm 0.10	96 \pm 10	7.50 \pm 0.77
Elderly	2.4 \pm 0.1	4.0 \pm 0.4	1.39 \pm 0.15	1.61 \pm 0.38	62 \pm 5	4.06 \pm 0.65
<i>P</i> value	0.34	<0.002	0.035	0.036	<0.006	<0.004